Fresh analysis indicates that patients who come off popular slimming jabs like semaglutide or tirzepatide tend to recover shed pounds much more quickly than those who stop traditional diet and exercise plans.
Published data in a prominent medical journal demonstrates that while obese people frequently drop substantial amounts of their body weight while undergoing treatment, the mass returns at an estimated rate of 0.8 kg per month once they quit.
"People purchasing such medications need to be informed of the danger of quick weight regain when the therapy ends," cautioned researcher Dr. Susan Jebb.
Such speed of regain implies a return to original mass in about a year and a half.
Analyzing Treatments
The research, which reviewed 37 of trials involving over 9,000 of patients, compared the results of these new drugs with other pills.
The team emphasize that people who lose weight through diet and exercise typically have a slower creep back—around 0.1 kg a month—post-intervention.
The Reason for the Rapid Regain
Doctors suggest the mechanism of the drugs accounts for the accelerated weight return.
These medications imitate a natural hormone called GLP-1, which helps regulate hunger.
"Sustained high doses of GLP-1 levels far above than normal could lead to the body to produce less of its endogenous GLP-1, and could diminish responsiveness to its actions," noted Dr. Adam Collins, a nutrition expert.
"Withdrawal of this medication means appetite is uncontrolled, making overeating far more likely."
A Lifelong Disease?
The NHS suggest the jabs for people with obesity-related medical conditions, alongside recommended lifestyle changes.
A number of clinicians say that, due to the likelihood of weight regain, the therapy should be considered ongoing.
This opinion is reinforced by pharmaceutical companies, who say that the results "highlight the persistent nature of excess weight," akin to managing diseases like hypertension.
Patient Experiences
People who have discontinued the jabs describe a sudden resurgence of cravings.
"It was like a switch flipping and I was suddenly ravenous," recalled an individual.
The struggle is compounded if users have not established lasting lifestyle or habit modifications during therapy.
Widespread Use
Survey data show that millions of people in the UK have used these injections in the past year, with interest remaining high.
- Adoption is higher among females compared to men.
- The 40s and 50s age group shows the highest level of interest.
- A large proportion access the drugs through private prescriptions rather than the NHS.
Finally, experts emphasize that while GLP-1 drugs are potent tools for weight loss, they are not a permanent solution and lasting health benefits hinges on integrated lifestyle support.
